This article was originally published on PharmaTimes http://www.pharmatimes.com/news/az_imfinzi_fails_in_head_and_neck_cancer_trial_1272151

AstraZeneca and MedImmune’s Imfinzi has failed to hit targets in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Related Posts